NattoPharma (NATTO)

Christian · desember 19, 2018, 3:43pm

Godt å sitte i trygge aksjer som NattoPharma når OSEBX stuper:

TekBot · desember 29, 2018, 11:34am

29/12-2018 12:33:23: (NATTO.OAX) Financial calendar

holmes · desember 29, 2018, 1:29pm

Godt å få det bekreftet at vi får kvartalsvise rapporter igjen.

TekBot · januar 2, 2019, 7:29am

02/01-2019 08:28:16: (NATTO.OAX) NATTO: MANDATORY NOTIFICATION OF TRADE AND DISCLOSURE OF LARGE SHAREHOLDING

Chairman of the Board and Primary Insider, Frode Marc Bohan, has on 31st
December 2018 through his company, Bohan & Co AS, purchased 200 000 shares in
NattoPharma ASA at a price of NOK 8.00 per share. The shares were acquired from
…

Vis børsmeldingen

NxT Capital Ltd., a company owned by Frode Marc Bohan.

At the same time, Bohan & Co AS has bought 75 000 shares at a price per share of
NOK 8.00 from Katarzyna Maresz. Katarzyna Maresz is a primary insider and a
member of the Board of Directors in NattoPharma ASA. After this transaction
Katarzyna Maresz control 25 000 shares and 100 000 options in NattoPharma ASA.

Further to this, Bohan & Co AS has agreed to transfer as a gift 10 000 shares to
Stella Bohan and 10 000 shares to Alexander Rye Bohan-Ellingsen, both being
related parties to Frode Marc Bohan. Stella Bohan and Alexander Rye
Bohan-Ellingsen will both hold 10 000 shares each in NattoPharma ASA after this
transaction.

Frode Bohan, chairman of the Board of Directors and primary insider in
NattoPharma ASA, will directly and indirectly through Bohan & Co AS (1,288,455
shares), TG Montgomery AS (1,735,122 shares), NxT Capital Ltd (252 852 shares)
and the related parties Patrycja Ratusinska (350,000 shares), Stella Bohan
(10,000 shares) and Alexander Rye Bohan-Ellingensen (10,000 shares) control 3
646 429 shares in NattoPharma ASA, representing 20,1% of the outstanding shares.
Mr. Bohan also hold 200 000 options in the company.

http://www.netfonds.no/quotes/release.php?id=20190102.OBI.20190102S11

holmes · januar 11, 2019, 8:50am

Kaydence styret oppgraderes (klippet fra Herman og Oxion på hegnar online)

holmes · januar 11, 2019, 5:02pm

Ikke mange aksjer omsatt på 9 tallet i dag, likevel litt interessant at det plutselig var tomt for selgere på 8. Spennende å se på mandag.

holmes · januar 15, 2019, 7:47am

Artikkel i FA om Kaydence

livsstil

I dag kl 00:0590

Biotek-gründere nær firedoblet prisingen

HELSE:Kaydence Pharma ble spunnet ut av NattoPharma til 5 kroner aksjen. Fire måneder senere er det gjort emisjon til kurs 17,50.
STEINAR GRINI
Børshøsten var tøff for de aller fleste investorer. Men for Frank Bjordal og Daniel Rosenbaums Kaydence Pharma var høsten et eventyr for selskapet som har utsatt planene om Merkur Market-notering for å vurdere Nasdaq-børsen i stedet.
Riktignok er ikke Kaydence børsnotert og riktignok er det kun eksisterende eiere som priser selskapet, men selskapet som hadde en prislapp på 17,5 millioner da det ble spunnet ut av NattoPharma fikk en verdi på 62 millioner da selskapet hentet ny kapital før jul.
Eksisterende eiere har satset 20 nye millioner kroner i selskapet som samtidig mener å ha gjort et viktig steg i prosessen mot FDA-godkjenning av sitt legemiddel i USA.
– Første steg mot aksept
– Vi har fått et gjennombrudd knyttet til det regulative i det vi har fått møte med FDA (Food and Drug Administration). Det er det første steget mot å få aksept for hele planen om kommersiell registrering av vårt farmasiprodukt i USA, sier styreleder Frank Bjordal i Kaydence Pharma.
Selskapet ble skilt ut fra NattoPharma som i dag selger vitaminet K2 som helsekost. Kaydence vil lage legemiddel av produktet slik at det kan brukes for å redusere mengden kalsium i blodårer.
– Det er ikke hverdagskost at et norsk selskap får et slikt møte med FDA. Det har gitt oss verdifull tilbakemelding om planene vi viste frem, og FDA hadde ingen betydelige innvendinger. Det reduserer risikoen for investorene våre, sier Bjordal.
Planen er å få produktet registrert som legemiddel i løpet av 2024.
– Vi har startet med en liten indikasjon, men problemet gjelder mange mennesker, og vi vil kunne legge til andre indikasjoner for legemiddelet etter hvert, sier Bjordal.
Toppnavn til styret
– Vi har en femårsplan med stadige milepæler, og vi vil prøve å hente ny finansiering knyttet til at vi når disse milepælene, og derigjennom få høyere prising ved hver milepæl. FDA-møtet var en stor milepæl i så måte, sier Daniel Rosenbaum til Finansavisen.
FDA-møtet er ikke bare blitt brukt for å lokke inn mer kapital til 3,5 ganger av verdien fire måneder tidligere, men er også brukt til å lokke inn et nytt lag av styremedlemmer gjennom Vaccibody-styreleder Tom Pike, Algeta-topp Geir Christian Melen.
– Det nye styret vil vurdere børsnotering av selskapet. Det er et antall muligheter, men Nasdaq i USA kan være et alternativ som kan gi oss høye multipler, sier Rosenbaum.
Bjordal istemmer at Merkur Market ikke lenger er et like aktuelt alternativ for selskapet.

Rahl · januar 15, 2019, 8:05am

Natto eier vel 45% av Kaydence, så her sitter vi fint

TekBot · januar 15, 2019, 8:38am

15/01-2019 09:38:05: (NATTO.OAX) Kaydence Pharma - Successful completion of Pre-IND meeting with FDA

Oslo, Norway (15 January 2019) - Kaydence Pharma AS, the development stage
pharmaceutical company spun-out of NattoPharma in 2017, reports today that it
has successfully completed a pre-IND (Investigational New Drug) meeting with the
…

Vis børsmeldingen

US Food and Drug Administration (FDA). At the meeting, the FDA addressed
questions regarding key components of the planned IND application and the
clinical/regulatory pathway for MQ7, Kaydence Pharma’s novel drug candidate for
the treatment of arterial stiffness in stable renal transplant recipients with
subclinical vitamin K deficiency.

“The continued positive momentum in the Kaydence Pharma development plan is very
encouraging and validates the strategic decision to spin the activity out of
NattoPharma’s ordinary supplement business in 2017. This decision ensures that
Kaydence continues to have both the correct focus and attention from competent
people to succeed. NattoPharma is very enthusiastic about this project and has
great faith in the future potential for a pharmaceutical drug based on the
extensive clinical understanding that NattoPharma has developed over the last 10
years of working with MK-7.” said Kjetil Ramsøy, CEO of NattoPharma.

The press release issued by Kaydence Pharma is attached to this announcement for
further reading.

X X X

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the exclusive international supplier of
MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as menaquinone-7 (MK
-7) with guaranteed actives and stability, clinical substantiation, and
international patents granted and pending; and now the new MenaQ7® Full
Spectrum, which delivers menaquinones 6, 7 and 9. The company has a multi-year
research and development program to substantiate and discover the health
benefits of Vitamin K2 for applications in the marketplace for functional food
and dietary supplements. With a global presence, the company has a North
American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma R&D
Ltd. in Cyprus. For more information, visit www.nattopharma.com or
www.menaq7.com.

For more information, please contact:

Kjetil Ramsøy, NattoPharma Chief Executive Officer

E-mail: kjetil.ramsoy@nattopharma.c

http://www.netfonds.no/quotes/release.php?id=20190115.OBI.20190115S15

nofun · januar 15, 2019, 3:05pm

Gikk ikke lang tid før den var tilbake på 8.x …

holmes · januar 15, 2019, 3:20pm

Folk er nok redd for å bli stuck i denne aksjen med lav likviditet, vi får håpe det bedrer seg og at noen tørr å kjøpe litt volum

nofun · januar 15, 2019, 3:50pm

Ja den er jo veldig lik slik som Kitron var før den tok av.

EDIT: ser jo litt bedre ut etter at noen tok 100 aksjer i sluttauksjonen

holmes · januar 18, 2019, 8:53pm

Labert volum, men ellers begynner det å ligne et trendbrudd synes jeg. Kan se ut som om kursen er i ferd med å etablere seg over SMA 50 og 200 på første gang på over et år.

holmes · januar 28, 2019, 10:45am

fra hegnar online

vestavind

I dag kl 08:2342

Jono skrev Ja, hvorfor ikke, men alt for kjedelig for meg dessverre. Liten omsetning, men positivt at kursen h…

Fikk svar på mailen til Nattopharma.
Beklager sen tilbakemelding. Jeg er på reise i USA, og har dessverre ikke fått tid til å komme tilbake på din epost før nå.

Vi, hverken ledelsen eller styret, er tilfreds med volumet, eller kursen, aksjen handles i for tiden. Som allerede annonsert så kommer vi med kvartalsvis rapportering igjen fra og med 1. kvartal 2019. Vi håper dette skal bidra til en bedre synlighet for investorer på Oslo Børs samt andre som er interessert i aksjen,

Vi har også annonsert at vi jobber med å få en analysedekning av aksjen. Jeg kan ikke gå i detaljer på dette uten at vi informerer alle aksjonærene, men det foreligger ingen grunn til at meldingen vi delte med markedet i November skulle endres på dette punktet. Mer informasjon vil komme den 13. februar når vi kommer med 4. kvartal 2018.

Jeg ønsker deg en fin helg.

Mvh
Kjetil

holmes · januar 28, 2019, 10:48am

Dette ble sagt i november

holmes · januar 31, 2019, 3:47pm

Dette ser jo ut som en fin meny på bagatelle

Ønsker de 6- eller 7 retter?

TekBot · februar 1, 2019, 12:09pm

31/01-2019 11:55:29: (NATTO.OAX) Financial calendar

holmes · februar 5, 2019, 8:09am

Gode muligheter for golden cross i Natto

TekBot · februar 5, 2019, 3:48pm

05/02-2019 16:48:05: (NATTO.OAX) Vitamin K2 & calcium paper, supported by Nattopharma, published in Frontiers in Cardiovascular Medicine

Journal publishes paper highlighting Vitamin K2 role in bone and vasculature,
completed as part of Norwegian Research Council grant
Oslo, Norway and Edison, NJ (5 FEB 2019) - Frontiers in Cardiovascular Medicine
…

Vis børsmeldingen

has published a new review paper examining calcium supplementation’s impact on
bone and cardiovascular health, and the role Vitamin K2 plays in proper calcium
utilization. The review paper is the result of a grant from the Norwegian
Research Council awarded to NattoPharma to fund a 4-year PhD project to document
the effect of calcium metabolism in the body based on the presence or absence of
vitamin K2, MK-7, where NattoPharma has provided MenaQ7® Vitamin K2 as MK-7 for
research conducted at the University of Maastricht, led by Professor Leon
Schurgers.*

According to the authors, the paper “The bone-vasculature axis: calcium
supplementation and the role of vitamin K”, provides an update on current
literature on calcium supplementation among post-menopausal women and chronic
kidney disease (CKD) patients and discusses underlying molecular mechanisms of
vascular calcification. Prof. Schurgers states that therapeutic strategies with
vitamin K2 treatment should be considered to prevent or hold progression of
vascular calcification as a consequence of excessive calcium intake.

“The work conducted in collaboration with NattoPharma under the Norwegian
Research Council grant will provide further evidence that calcium without
adequate vitamin K2 consumption might end up in the soft tissues where it is not
wanted, rather than in the bone matrix, where it is needed,” says Prof.
Schurgers, Professor of Biochemistry of Vascular Calcification and Vice Chair of
Biochemistry at the Cardiovascular Research Institute Maastricht (CARIM),
Maastricht University; and senior author and leader of the research project. “In
a recent study by Bolland et al., it was shown that calcium supplementation of
postmenopausal women was associated with a beneficial effect on bone, but also
with increased myocardial infarction, suggesting detrimental effects on the
vascular system possibly by inducing increased vascular calcification. As
calcium supplementation is needed for bone, the precipitation in the vessel wall
needs to be inhibited.”

The paper is significant because it adds to the growing body of evidence
substantiating MenaQ7® Vitamin K2 as a bone- and cardiovascular-support
nutrient, according to NattoPharma Chief Medical Officer Dr. Hogne Vik.

“Compromised bone and heart health are not merely age-related issues; rather,
they are signs of a core nutrient deficiency: vitamin K2,” says Vik.
"NattoPharma has driven the research confirming vitamin K2’s important health
benefits, showing in human studies with healthy participants that the
progression of hardening of the arteries can be halted and even regressed, and
that bone strength can be improved with daily supplementation of MenaQ7 Vitamin
K2.

“We are proud that our partnership with Maastricht University and this
prestigious grant have given us an opportunity to further the understanding of
the necessity of obtaining adequate vitamin K2 for human health,” Dr. Vik adds.
“We hope these findings will earn the attention of manufacturers and consumers
alike, helping them to recognize that all calcium supplementation must be paired
with vitamin K2 so bone and heart health can be simultaneously supported.”

Prof. Schurgers’ research is additionally funded in part via the European
Union’s Horizon 2020 research and innovation programme under the Marie
Sklodowska-Curie grant agreement No. 722609 in which NattoPharma is partner.

References:

Wasilewski GB, Vervloet MG, Schurgers LJ. The Bone-Vasculature Axis: Calcium
Supplementation and the Role of Vitamin K. Front. Cardiovasc. Med, 5 Feb 2019.
https://doi.org/10.3389/fcvm.2019.00006

XXX

About NattoPharma and MenaQ7®

NattoPharma ASA, based in Norway, is the supplement industry world leader in
vitamin K2 research and development. NattoPharma is the exclusive international
supplier of MenaQ7® Vitamin K2 as MK-7, the best documented, vitamin K2 as
menaquinone-7 (MK-7) with guaranteed actives and stability, clinical
substantiation, and international patents granted and pending; and now the new
MenaQ7® Full Spectrum, which delivers menaquinones 6, 7, and 9. The company has
a multi-year research and development program to substantiate and discover the
health benefits of Vitamin K2 for applications in the marketplace for functional
food and dietary supplements, in addition to exclusive access to the research
efforts of its pharmaceutical arm, Kaydence Pharma AS (est. 2017), outside of
the pharmaceutical domain. With a global presence, the company established its
North American subsidiary, NattoPharma USA, Inc., in Edison, NJ, and NattoPharma
R&D Ltd. in Cyprus. For more information, visit www.nattopharma.com or
www.menaq7.com.

For more information, please contact:

Kate Quackenbush, NattoPharma Director of Communications

P: 609-643-0749 x 220; E: kate.quackenbush@nattopharma

http://www.netfonds.no/quotes/release.php?id=20190205.OBI.20190205S71

TekBot · februar 6, 2019, 7:46am